Plague treatment showdown: ciprofloxacin vs doxycycline
NCT ID NCT01243437
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the antibiotic ciprofloxacin works as well as doxycycline for treating plague, a serious bacterial infection. Only 5 people in Uganda took part, and they were randomly assigned to one of the two drugs. The goal was to see if ciprofloxacin could be a good alternative treatment, especially in places where other options are limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ciprofloxacin and doxycycline
- What this could lead to
- If ciprofloxacin works as well as doxycycline, it could provide another treatment option for plague, especially in areas where doxycycline is hard to get or can't be used.
- What could go wrong
- This is a very small study (only 5 people) and early-stage (Phase 2), so results may not apply broadly. Ciprofloxacin's effectiveness against plague in humans is still not well proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
5 people
The number who actually took part.
- Start date
-
Dec 2010
- Finished
-
Jun 2013
- Lead sponsor
-
A government agency
The lead sponsor is a US federal agency other than the NIH.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
8 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Suspect cases of plague will be eligible and will be asked to give consent for study enrollment using the following criteria: 1. any person, including women and persons who are minorities, who; 2. must be aged 8 years or older, and; 3. must have had potential exposure to rodents and/or fleas or contact with a confirmed plague case, and; 4. must have a fever of at least 38ºC that developed rapidly, and have at least one of the following: * One or more buboes, defined as a tender lymph node swelling \> 1cm in diameter, or; * Clinical suspicion of pneumonic plague (e.g. prostration, cough, increased respiratory rate, hemoptysis and/or purulent sputum), or * Clinical suspicion of cutaneous plague (lesion) * Clinical suspicion of plague and epidemiologic link with other cases Exclusion Criteria: * Patients with suspected plague illness will be considered ineligible for the study and will be excluded from study enrollment using the following criteria: * Any women who is pregnant, or; * Any woman who is breast-feeding, or; * Any person aged \< 8 years of age, or; * Any patient with: * signs of plague meningitis * hypotension unresponsive to fluid therapy * an illness severity score of \> 16 at time of enrollment (see below) * known allergy to ciprofloxacin or doxycycline * taken tetracyclines, quinolones, gentamicin, streptomycin, trimethoprim-sulfamethoxazole, or chloramphenicol in the 24 hours preceding study enrollment Patients who are pregnant, breast-feeding, or aged \< 8 years will be excluded because doxycycline has a relative contraindication for use in these populations due to drug deposition in calcifying areas of bones and teeth, enamel hypoplasia, and decreased linear skeletal growth rate. \[22, 23\] Please see section 10.2 for additional background describing the reasoning to exclude patients from these populations. Please see section 3.5 for the specifics regarding the timing of urine pregnancy testing. The illness severity score is a composite measure adapted from the APACHE-II and Glasgow Coma scores that estimates the severity of a patient's illness at enrollment. Because most clinic locations are remote with little or no laboratory capacity, the illness severity score utilizes only non-biochemical parameters. Patients will not be tested for Human Immunodeficiency Virus (HIV), and known or suspected HIV-positive patients will not be excluded. Because this study will be conducted in a remote region of Uganda where no prisons are located, the enrollment of prisoners is not applicable to our study. If for some unforeseen reason a prisoner presents to a study clinic location for treatment of suspected plague, the prisoner will be excluded from the trial. All study resources will be available and treatment following the UMOH national plague treatment guidelines will be offered to patients with suspected plague at the UMOH collaborating clinics who are not eligible for enrollment or who declined to consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Plague are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uganda Ministry of Health: selected Arua and Nebbi district health centres
Arua, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.